Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.
Xeloda is a highly effective targeted oral chemotherapy offering patients a survival advantage when taken on its own or in combination with other anticancer drugs. Xeloda is converted to the active cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells, thus reducing damage to healthy cells. Xeloda tablets can be taken by patients in their own home, reducing the number of hospital visits.1
In Bangladesh Xeloda is approved for the following indications.2
Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of a taxane and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Xeloda is indicated as adjuvant treatment of patients with colon cancer.
Xeloda is indicated for the treatment of patients with metastatic colorectal cancer.
Xeloda is indicated as first-line treatment of patients with advanced oesophagogastric cancer.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Xeloda is available as
Film-coated tablets 500 mg
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Global Website: Investors. Xeloda in combination with oxaliplatin shown to be effective in early colon cancer (2009, July 20). [Internet; cited 2018, December 03]. Retrieved from https://www.roche.com/investors/updates/inv-update-2009-07-20.htm
Xeloda Product Information BD English Ro 09-1978 September 2020
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.